These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36970726)

  • 61. The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.
    Wang LH; Aberin MAE; Wu S; Wang SP
    Biochem Soc Trans; 2021 Jun; 49(3):1041-1054. PubMed ID: 34156443
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes.
    Shinsky SA; Hu M; Vought VE; Ng SB; Bamshad MJ; Shendure J; Cosgrove MS
    J Mol Biol; 2014 Jun; 426(12):2283-99. PubMed ID: 24680668
    [TBL] [Abstract][Full Text] [Related]  

  • 63. LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α-2,3 sialylation via PI3K/Akt signaling.
    Hu J; Shan Y; Ma J; Pan Y; Zhou H; Jiang L; Jia L
    Int J Cancer; 2019 Jul; 145(2):450-460. PubMed ID: 30613961
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Histone H3 lysine 4 methyltransferase KMT2D.
    Froimchuk E; Jang Y; Ge K
    Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Structural insights on the KMT2-NCP interaction.
    Yang Z; Zepeda R; Dou Y
    Biochem Soc Trans; 2023 Feb; 51(1):427-434. PubMed ID: 36695549
    [TBL] [Abstract][Full Text] [Related]  

  • 66. H3K18 & H3K23 acetylation directs establishment of MLL-mediated H3K4 methylation.
    Fox GC; Poncha KF; Smith BR; van der Maas LN; Robbins NN; Graham B; Dowen JM; Strahl BD; Young NL; Jain K
    bioRxiv; 2024 May; ():. PubMed ID: 38798640
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Recent clinical advances in PI3K inhibitors on colorectal cancer.
    Zhu M; Jin Q; Xin Y
    Pharmazie; 2021 Dec; 76(12):568-573. PubMed ID: 34986950
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of PI3K inhibitors in advanced breast cancer.
    Verret B; Cortes J; Bachelot T; Andre F; Arnedos M
    Ann Oncol; 2019 Dec; 30 Suppl 10():x12-x20. PubMed ID: 31928690
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer.
    Lu K; Tao H; Si X; Chen Q
    Front Oncol; 2018; 8():502. PubMed ID: 30488017
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
    Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
    J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
    Serra V; Scaltriti M; Prudkin L; Eichhorn PJ; Ibrahim YH; Chandarlapaty S; Markman B; Rodriguez O; Guzman M; Rodriguez S; Gili M; Russillo M; Parra JL; Singh S; Arribas J; Rosen N; Baselga J
    Oncogene; 2011 Jun; 30(22):2547-57. PubMed ID: 21278786
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
    Fiascarelli A; Merlino G; Capano S; Talucci S; Bisignano D; Bressan A; Bellarosa D; Carrisi C; Paoli A; Bigioni M; Tunici P; Irrissuto C; Salerno M; Arribas J; de Stanchina E; Scaltriti M; Binaschi M
    Breast Cancer Res Treat; 2023 May; 199(1):13-23. PubMed ID: 36913051
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
    Miricescu D; Totan A; Stanescu-Spinu II; Badoiu SC; Stefani C; Greabu M
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375317
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
    Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
    Hernandez-Aya LF; Gonzalez-Angulo AM
    Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
    Wang S; Zhang Y; Ren T; Wu Q; Lu H; Qin X; Liu Y; Ding H; Zhao Q
    Cell Death Dis; 2020 Jun; 11(6):491. PubMed ID: 32606352
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
    Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
    Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
    Brady SW; Zhang J; Seok D; Wang H; Yu D
    Mol Cancer Ther; 2014 Jan; 13(1):60-70. PubMed ID: 24249715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.